In a report released today, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Amicus (FOLD), with a price target of $18.00. The company’s shares closed last Monday at $7.86, close to its 52-week low of $7.11.
According to TipRanks.com, Chattopadhyay is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -11.7% and a 32.2% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Precision BioSciences Inc, and Voyager Therapeutics Inc.
Amicus has an analyst consensus of Strong Buy, with a price target consensus of $21.33, representing a 174.2% upside. In a report issued on October 3, Cowen & Co. also maintained a Buy rating on the stock with a $31.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.62 and a one-year low of $7.11. Currently, Amicus has an average volume of 3.55M.
Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FOLD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amicus Therapeutics, Inc. engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease.
